Results: EGFRvIII expression was detected in 42% of HNSCC tumors where EGFRvIII was always found in conjunction with wild-type EGFR. HNSCC cells expressing EGFRvIII showed increased proliferation in vitro and increased tumor volumes in vivo compared with vector-transfected controls. Furthermore, EGFRvIII-transfected HNSCC cells showed decreased apoptosis in response to cisplatin and decreased growth inhibition following treatment with C225 compared with vector-transfected control cells.
Very real potential in head and neck cancer. Potential catalyst if (when?) they move in to the clinical studies for this indication. This woudl be very good use of new capital (i.e. expanding indication whilst phase II is ongoing. It would be great to start those discussions with FDA this year and take advantage of new regulatory environment and perhaps even get SPA agreement on "straight to phase III approach" for head and neck cancer (i.e by-pass phase II altogether) !